Home > Cardiology > ACC/WCC 2020 > Heart Failure and Cardiomyopathies > Vericiguat shows beneficial effects in a very high-risk HF population

Vericiguat shows beneficial effects in a very high-risk HF population

Presented By
Prof. Paul Armstrong, University of Alberta, Canada
Conference
ACC 2020
Trial
Phase 3, Victoria
Results from the phase 3 VICTORIA trial –which included high-risk heart failure (HF) patients– showed that vericiguat was superior to placebo at improving heart failure outcomes [1,2]. Prof. Paul Armstrong (University of Alberta, Canada) presented the results of the 42-country Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction (VICTORIA) trial, which was designed to evaluate vericiguat compared with placebo among patients with chronic heart failure due to reduced ejection fraction (HFrEF). Vericiguat is a first-in-class stimulator of soluble guanylate cyclase (sGC) activity that also enhances sGC sensitivity to endogenous nitric oxide (NO). Deficiency in sGC-derived cyclic guanosine monophosphate (cGMP) causes both myocardial dysfunction and i...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on